0001683168-23-005538.txt : 20230811 0001683168-23-005538.hdr.sgml : 20230811 20230811080509 ACCESSION NUMBER: 0001683168-23-005538 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230811 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenetic Biosciences, Inc. CENTRAL INDEX KEY: 0001534525 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452952962 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37937 FILM NUMBER: 231161596 BUSINESS ADDRESS: STREET 1: 945 CONCORD ST. CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: 781-778-7720 MAIL ADDRESS: STREET 1: 945 CONCORD ST. CITY: FRAMINGHAM STATE: MA ZIP: 01701 FORMER COMPANY: FORMER CONFORMED NAME: General Sales & Leasing, Inc. DATE OF NAME CHANGE: 20130227 FORMER COMPANY: FORMER CONFORMED NAME: GENERAL AIRCRAFT INC. DATE OF NAME CHANGE: 20111108 8-K 1 xenetic_8k.htm CURRENT REPORT
0001534525 false 0001534525 2023-08-11 2023-08-11 0001534525 XBIO:CommonStock0.001ParValuePerShareMember 2023-08-11 2023-08-11 0001534525 XBIO:PurchaseWarrantsMember 2023-08-11 2023-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

 

FORM 8-K

________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 11, 2023

________________________

 

Xenetic Biosciences, Inc.

(Exact name of registrant as specified in charter)

 

Nevada   001-37937   45-2952962
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

945 Concord Street  
Framingham, Massachusetts 01701
(Address of principal executive offices) (Zip Code)

 

(781) 778-7720

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   XBIO   The Nasdaq Stock Market
Purchase Warrants   XBIOW   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 11, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended June 30, 2023 and providing a corporate update.

 

The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

FORWARD-LOOKING STATEMENTS

 

This Form 8-K, including the press release, contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K, including the press release, other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements or results to differ materially from the activities and results anticipated in forward-looking statements. These risks and uncertainties include those described in the “Risk Factors” section as detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission (“SEC”), including the Company’s annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak (including any new variant strains of the underlying virus), geopolitical events, such as the Russian invasion of Ukraine, and financial market instability or disruptions to the banking system due to bank failures, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this Form 8-K, including the press release, speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated August 11, 2023 pertaining to the financial results of the Company for the three months ended June 30, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  XENETIC BIOSCIENCES, INC.
   
  By: /s/ James Parslow                                        
Date: August 11, 2023 Name:   James Parslow
  Title:     Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
 EX-99.1 2 xenetic_ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

 

 

 

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

 

- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors

 

FRAMINGHAM, MA – (August 11, 2023) – Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2023.

 

"Since the beginning of 2023, we have taken important, fundamental steps to further advance our DNase-based oncology platform. We have secured strategic collaborations, bolstered our team’s expertise and identified development and regulatory pathways that give us line of sight towards our first in human clinical study. Moving forward, we intend to establish additional strategic collaborations that we believe will enable us to expedite this pathway to the clinic and expand our opportunities and value proposition,” commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

 

Recent Highlights:

 

·Executed the first Collaborator Statement of Work (“SOW”) as part of the previously announced collaboration agreement with VolitionRx and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer. The Company's collaboration with Volition is an early exploratory program to evaluate the potential combination of Volition's Nu.Q® technology and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers for which current CAR T cell therapies have shown limited or no effect; and
·Continued participation in conferences and investor-focused events. To watch the replay of the most recent event, go to https://us02web.zoom.us/webinar/register/WN_r_Ed8vT2QkulEUkTrP0GuQ#/registration.

 

Summary of Financial Results for Second Quarter 2023

 

Net loss for the quarter ended June 30, 2023 was approximately $1.1 million. Research & development expenses for the three months ended June 30, 2023 decreased by approximately $1.2 million, or 56.5%, to approximately $0.9 million from approximately $2.1 million in the comparable quarter in 2022. The decrease was primarily due to in-process research and development (“IPR&D”) expense of $1.3 million associated with the Company’s licensing of the DNase oncology platform during the three months ended June 30, 2022. There was no similar expense in 2023. Excluding the $1.3 million of IPR&D expense from total R&D expense of $2.1 million for the three months ended June 30, 2022, R&D expense for the three months ended June 30, 2023 increased by $0.1 million, or 16.9%, primarily due to increased spending related to our pre-clinical development efforts associated with our DNase platform. Royalty payments of approximately $0.7 million were received from our sublicense with Takeda Pharmaceuticals Co. Ltd in the three months ended June 30, 2023, representing an approximate 56.2% increase over the same period in 2022. General and administrative expenses for the three months ended June 30, 2023 decreased by approximately $0.1 million, or 7.8%, to approximately $0.9 million from approximately $1.0 million in the comparable quarter in 2022. The decrease was primarily due to a decrease in legal fees and share-based expense during the three months ended June 30, 2023 compared to the same period in 2022.

 

The Company ended the quarter with approximately $10.7 million of cash and no debt.

 

Non-GAAP Measures

 

In our narrative discussion of operations above, we exclude the impact of non-cash expenses from certain operating measures, which narrative discussion includes reconciliation of such adjusted financial measures to the directly comparable GAAP financial measure. We believe these adjusted operating measures may provide investors with useful information regarding our underlying performance from period to period and allow investors to better understand our results of operations. Management uses these adjusted measures when assessing the performance of the business.

 

 

   

 

 

About Xenetic Biosciences

 

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.


For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.

 

Forward-Looking Statements

 

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including, but not limited to, statements regarding: all statements regarding expectations for our DNase-base oncology platform, including our plan to advance the DNase-based oncology program toward Phase 1 clinical development, our intention to establish additional strategic collaborations, our belief that additional strategic collaborations will enable us to expedite its pathway to the clinic and expand our opportunities and value proposition, our progress towards our first in human clinical study, our expectations regarding the potential development of proprietary adoptive cell therapies potentially targeting multiple types of solid cancers for which current CAR T cell therapies have shown limited or no effect, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase, XCART or PolyXen technologies; (5) the ability of the Company to implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the Russian invasion of Ukraine, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

 

Contact:

 

JTC Team, LLC

Jenene Thomas

(833) 475-8247

xbio@jtcir.com

 

 

 

 2 

 

 EX-101.SCH 3 xbio-20230811.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 xbio-20230811_def.xml XBRL DEFINITION FILE EX-101.LAB 5 xbio-20230811_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, $0.001 par value per share Purchase Warrants Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 xbio-20230811_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 11, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 11, 2023
Entity File Number 001-37937
Entity Registrant Name Xenetic Biosciences, Inc.
Entity Central Index Key 0001534525
Entity Tax Identification Number 45-2952962
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 945 Concord Street
Entity Address, City or Town Framingham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01701
City Area Code (781)
Local Phone Number 778-7720
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, $0.001 par value per share  
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol XBIO
Security Exchange Name NASDAQ
Purchase Warrants  
Title of 12(b) Security Purchase Warrants
Trading Symbol XBIOW
Security Exchange Name NASDAQ
XML 9 xenetic_8k_htm.xml IDEA: XBRL DOCUMENT 0001534525 2023-08-11 2023-08-11 0001534525 XBIO:CommonStock0.001ParValuePerShareMember 2023-08-11 2023-08-11 0001534525 XBIO:PurchaseWarrantsMember 2023-08-11 2023-08-11 iso4217:USD shares iso4217:USD shares 0001534525 false 8-K 2023-08-11 Xenetic Biosciences, Inc. NV 001-37937 45-2952962 945 Concord Street Framingham MA 01701 (781) 778-7720 false false false false Common Stock, $0.001 par value per share XBIO NASDAQ Purchase Warrants XBIOW NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " 8T0 !X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " "D0 M7)!Z;HJT #X 0 &@ M@ 'M$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "D M0 M799!YDAD! #/ P $P @ '2$@ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "0 ) #X" <% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 22 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://xeneticbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports xenetic_8k.htm xbio-20230811.xsd xbio-20230811_def.xml xbio-20230811_lab.xml xbio-20230811_pre.xml xenetic_ex9901.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "xenetic_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "xbio-20230811_def.xml" ] }, "inline": { "local": [ "xenetic_8k.htm" ] }, "labelLink": { "local": [ "xbio-20230811_lab.xml" ] }, "presentationLink": { "local": [ "xbio-20230811_pre.xml" ] }, "schema": { "local": [ "xbio-20230811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 2, "memberStandard": 0, "nsprefix": "XBIO", "nsuri": "http://xeneticbio.com/20230811", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "xenetic_8k.htm", "contextRef": "AsOf2023-08-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://xeneticbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "xenetic_8k.htm", "contextRef": "AsOf2023-08-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "XBIO_CommonStock0.001ParValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, $0.001 par value per share" } } }, "localname": "CommonStock0.001ParValuePerShareMember", "nsuri": "http://xeneticbio.com/20230811", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "domainItemType" }, "XBIO_PurchaseWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Warrants" } } }, "localname": "PurchaseWarrantsMember", "nsuri": "http://xeneticbio.com/20230811", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xeneticbio.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001683168-23-005538-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-23-005538-xbrl.zip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end